ALT
Altimmune, Inc.
There isn't enough reported data to score ALT yet.
ALT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALT's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
ALT PE Valuation
ALT has no meaningful PE right now: it lost money over the past year.
ALT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ALT's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
ALT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.71 | +$0.36 |
| Q2 2026 | -$0.77 | +$0.41 |
| Q1 2026 | -$0.92 | +$0.34 |
| Q4 2025 | -$1.00 | +$0.34 |
| Q3 2025 | -$1.07 | +$0.50 |
| Q2 2025 | -$1.18 | +$0.46 |
| Q1 2025 | -$1.26 | +$0.35 |
| Q4 2024 | -$1.34 | +$0.32 |
ALT is still losing money, but far less than before: $0.71 per share over the past year, against $2.41 at its worst in early 2022.
ALT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $26K | +420% |
| Q3 2025 | $5K | 0% |
| Q2 2025 | $5K | 0% |
| Q1 2025 | $5K | 0% |
| Q4 2024 | $5K | -86% |
| Q3 2024 | $5K | -99% |
| Q2 2024 | $5K | -17% |
| Q1 2024 | $5K | -76% |
ALT's revenue is recovering but still below its 2021 peak: $26,000 last quarter, up 420% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -111127% | +386193 points |
| Q3 2025 | -417180% | +78160 points |
| Q2 2025 | -458440% | +76460 points |
| Q1 2025 | -436300% | +99580 points |
| Q4 2024 | -497320% | -406447 points |
| Q3 2024 | -495340% | -489114 points |
| Q2 2024 | -534900% | -234783 points |
| Q1 2024 | -535880% | -432266 points |
ALT's operating margin was −111127% last quarter, up 386193 points from the same quarter a year ago.
ALT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.8M | -$25.9M |
| Q1 2026 | -$21M | -$4.1M |
| Q4 2023 | -$16.5M | +$811K |
| Q3 2023 | -$20.5M | -$5.4M |
| Q2 2023 | -$19.4M | -$2.7M |
| Q1 2023 | -$19.5M | -$5.9M |
| Q4 2022 | -$17.3M | +$4.8M |
| Q3 2022 | -$15.1M | +$2.7M |
ALT has burned cash in almost every quarter: −$102M over the past year, against −$66M the year before.
ALT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +19.8M shares |
| 1 year | +152% | +124M shares |
| 3 years | +310% | +155M shares |
| 5 years | +427% | +166M shares |
| Available history | +1464% | +192M shares |
ALT has 205M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
ALT Net Leverage
ALT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 4.7 | Oversold |
ALT's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
ALT PE vs Healthcare Sector
ALT has no meaningful PE right now: it lost money over the past year.
ALT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.31 | 30% below |
| 20 week MA | $2.77 | 42% below |
| 50 week MA | $3.33 | 52% below |
| 100 week MA | $4.23 | 62% below |
| 200 week MA | $5.48 | 71% below |
ALT is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
ALT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.80 | $11.5 | +536% |
| 2021 | $11.5 | $9.20 | -20% |
| 2022 | $9.20 | $15.3 | +67% |
| 2023 | $15.3 | $11.3 | -27% |
| 2024 | $11.3 | $7.67 | -32% |
| 2025 | $7.67 | $3.86 | -50% |
| 2026 YTD | $3.86 | $1.61 | -58% |
ALT has finished three years in a row lower, and it's down 58% so far in 2026.